Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer
dc.contributor.author | Xiang, W | |
dc.contributor.author | Zhao, L | |
dc.contributor.author | Han, X | |
dc.contributor.author | Xu, T | |
dc.contributor.author | Kregel, S | |
dc.contributor.author | Wang, M | |
dc.contributor.author | Miao, B | |
dc.contributor.author | Qin, C | |
dc.contributor.author | Wang, M | |
dc.contributor.author | McEachern, D | |
dc.contributor.author | Lu, J | |
dc.contributor.author | Bai, L | |
dc.contributor.author | Yang, CY | |
dc.contributor.author | Kirchhoff, PD | |
dc.contributor.author | Takyi-Williams, J | |
dc.contributor.author | Wang, L | |
dc.contributor.author | Wen, B | |
dc.contributor.author | Sun, D | |
dc.contributor.author | Ator, M | |
dc.contributor.author | Mckean, R | |
dc.contributor.author | Chinnaiyan, AM | |
dc.contributor.author | Wang, S | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2024-01-23T21:11:45Z | |
dc.date.available | 2024-01-23T21:11:45Z | |
dc.date.issued | 2023-09-28 | |
dc.identifier.issn | 0022-2623 | |
dc.identifier.issn | 1520-4804 | |
dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pubmed/37683104 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/192125 | en |
dc.description.abstract | We report herein the discovery and extensive characterization of ARD-1676, a highly potent and orally efficacious PROTAC degrader of the androgen receptor (AR). ARD-1676 was designed using a new class of AR ligands and a novel cereblon ligand. It has DC50 values of 0.1 and 1.1 nM in AR+ VCaP and LNCaP cell lines, respectively, and IC50 values of 11.5 and 2.8 nM in VCaP and LNCaP cell lines, respectively. ARD-1676 effectively induces degradation of a broad panel of clinically relevant AR mutants. ARD-1676 has an oral bioavailability of 67, 44, 31, and 99% in mice, rats, dogs, and monkeys, respectively. Oral administration of ARD-1676 effectively reduces the level of AR protein in the VCaP tumor tissue in mice and inhibits tumor growth in the VCaP mouse xenograft tumor model without any sign of toxicity. ARD-1676 is a highly promising development candidate for the treatment of AR+ human prostate cancer. | |
dc.format.medium | Print-Electronic | |
dc.language | eng | |
dc.publisher | American Chemical Society (ACS) | |
dc.subject | 32 Biomedical and Clinical Sciences | |
dc.subject | 3211 Oncology and Carcinogenesis | |
dc.subject | Prostate Cancer | |
dc.subject | Cancer | |
dc.subject | Urologic Diseases | |
dc.subject | Biotechnology | |
dc.subject | 5 Development of treatments and therapeutic interventions | |
dc.subject | 5.1 Pharmaceuticals | |
dc.subject | Cancer | |
dc.title | Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer | |
dc.type | Article | |
dc.identifier.pmid | 37683104 | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/192125/2/xiang-et-al-2023-discovery-of-ard-1676-as-a-highly-potent-and-orally-efficacious-ar-protac-degrader-with-a-broad.pdf | |
dc.identifier.doi | 10.1021/acs.jmedchem.3c01264 | |
dc.identifier.doi | https://dx.doi.org/10.7302/22125 | |
dc.identifier.source | Journal of Medicinal Chemistry | |
dc.description.version | Published version | |
dc.date.updated | 2024-01-23T21:11:42Z | |
dc.identifier.orcid | 0000-0001-8996-4065 | |
dc.identifier.orcid | 0000-0002-5908-4072 | |
dc.identifier.orcid | 0000-0001-8108-1698 | |
dc.identifier.orcid | 0000-0003-1025-2925 | |
dc.identifier.orcid | 0000-0002-5445-0109 | |
dc.identifier.orcid | 0000-0002-6406-2126 | |
dc.identifier.orcid | 0000-0001-9282-3415 | |
dc.identifier.orcid | 0000-0002-8782-6950 | |
dc.description.filedescription | Description of xiang-et-al-2023-discovery-of-ard-1676-as-a-highly-potent-and-orally-efficacious-ar-protac-degrader-with-a-broad.pdf : Published version | |
dc.identifier.volume | 66 | |
dc.identifier.issue | 18 | |
dc.identifier.startpage | 13280 | |
dc.identifier.endpage | 13303 | |
dc.identifier.name-orcid | Xiang, W | |
dc.identifier.name-orcid | Zhao, L | |
dc.identifier.name-orcid | Han, X | |
dc.identifier.name-orcid | Xu, T; 0000-0001-8996-4065 | |
dc.identifier.name-orcid | Kregel, S | |
dc.identifier.name-orcid | Wang, M; 0000-0002-5908-4072 | |
dc.identifier.name-orcid | Miao, B | |
dc.identifier.name-orcid | Qin, C; 0000-0001-8108-1698 | |
dc.identifier.name-orcid | Wang, M | |
dc.identifier.name-orcid | McEachern, D | |
dc.identifier.name-orcid | Lu, J | |
dc.identifier.name-orcid | Bai, L; 0000-0003-1025-2925 | |
dc.identifier.name-orcid | Yang, CY; 0000-0002-5445-0109 | |
dc.identifier.name-orcid | Kirchhoff, PD | |
dc.identifier.name-orcid | Takyi-Williams, J | |
dc.identifier.name-orcid | Wang, L | |
dc.identifier.name-orcid | Wen, B | |
dc.identifier.name-orcid | Sun, D; 0000-0002-6406-2126 | |
dc.identifier.name-orcid | Ator, M | |
dc.identifier.name-orcid | Mckean, R | |
dc.identifier.name-orcid | Chinnaiyan, AM; 0000-0001-9282-3415 | |
dc.identifier.name-orcid | Wang, S; 0000-0002-8782-6950 | |
dc.working.doi | 10.7302/22125 | en |
dc.owningcollname | Internal Medicine, Department of |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.